全球抗癌药物市场-2022-2029

市场概况

在预测期内（2022-2029 年），癌症治疗的市场规模预计将以 7.3% 的复合年增长率增长。

抗癌药物是旨在通过阻断某些有助于恶性细胞生长和扩散的分子（如蛋白质和 DNA）来减缓癌症生长和扩散的药物。肺癌、结肠癌、乳腺癌、肾癌和其他器官的癌症在人群中很普遍。癌症治疗很大程度上取决于疾病的进展程度。它通常包括放射疗法、化学疗法、手术和其他癌症治疗。目前正在研究免疫疗法、靶向疗法、激素疗法和干细胞移植，并正在进行临床试验。

市场动态

主要驱动力是由于癌症发病率上升导致对抗癌药物的需求增加，对精准医疗的需求增加，製药公司之间的合作伙伴关係增加，最近的技术进步，癌症研究活动的增加，全球是老年人口的增加。此外，全球医疗保健支出的增加。

最近的技术进步和信息利用率的提高预计将推动市场增长。

先进的医疗设备、大数据、人工智能和移动应用程序推动了更好的患者参与。大数据通过提供患者导航、患者报告的结果、高风险患者的识别、患者满意度评分和适当的治疗来促进护理。AI 使用 DL 算法和卷积神经网络 (CNN) 来分析来自肿瘤图像的像素级信息。例如，许多国家越来越多地使用移动应用程序是技术进步的结果，这些进步可以增强癌症诊断、治疗、依从性和患者体验的其他方面。基因泰克还批准了一种名为嵌合抗原受体 T 细胞（CAR-T）疗法的新药，以改善 CAR-T 疗法。虽然这种疗法对患者来说相当昂贵，但首个 CAR-T 疗法的推出也见证了一项创新的基于绩效的合同的揭幕，以使其更容易获得。

此外，新型放射性标记药物的持续存在降低了癌症患者的风险和死亡率。该药物将放射性同位素 LU 附着在奥曲□上，奥曲□与肿瘤细胞结合，使辐射成为可能，并直接靶向癌细胞。因此，预计最近的技术进步将推动市场发展。

抑製剂

然而，与使用抗癌药物相关的副作用的发生以及与抗癌药物开发相关的高成本是预计阻碍肿瘤药物市场增长的几个主要因素。

行业分析

肿瘤药物市场根据各种行业因素（如未满足的需求、定价分析、供应链分析和监管分析）对市场进行深入分析。

细分分析

靶向治疗部分预计将占癌症治疗市场的最大市场份额。

靶向治疗领域在 2021 年占据了最大的市场份额。该细分市场受益于与传统疗法相比副作用更少、更具成本效益以及增加运动次数的疗法。此外，靶向疗法包括激素疗法、细胞凋亡诱导剂、基因表达调节剂、血管生成抑製剂、PARP抑製剂、信号抑製剂和毒素递送分子。这些药物减缓癌细胞的生长和扩散，并限制对正常细胞的伤害。此外，该地区的 FDA 批准也在增加。例如，Trodelvy（sacituzumab govitecan-hziy）于2020年4月获得美国食品药品监督管理局批准，用于治疗成年三阴性乳腺癌患者。Trodelvy 是针对 Trop-2 受体的 Trop-2 定向抗体和有助于癌症生长、分裂和传播的拓扑异构□抑製剂的组合。此外，tabrecta（卡马替尼）于 2020 年 5 月获得美国 FDA 批准用于治疗成人非小细胞肺癌（NSCLC）患者，使其成为 FDA 批准的首个用于治疗具有特定突变的 NSCLC 的靶点。一种药物。因此，从上述描述来看，市场细分在预测期内占据了最大的市场份额。

区域分析

预计北美将在全球抗癌药物市场占有最大的市场份额。

2021 年，北美的收入份额最高。癌症患病率的增加、癌症治疗的创新、治疗临床试验的增加、该地区 FDA 批准的增加以及市场参与者的产品发布将在预测期内推动市场。这是一个因素。例如，美国癌症协会估计，到 2020 年，美国将有 180 万例新的癌症病例和 606,520 例癌症死亡。与此同时，到 2021 年，估计美国将诊断出 190 万例新的癌症病例，将有 608,570 例癌症死亡。因此，癌症治疗药物的采用正在取得进展。此外，2021 年 5 月，安进的 LUMAKRAS（sotrasib）获得 FDA 批准，用于治疗具有 KRAS G12C 突变的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。因此，从上述描述来看，北美地区在预测期内占据了最大的市场份额。

竞争格局

肿瘤药物市场的主要关键参与者是Pfizer, Inc.、Novartis、Amgen Inc、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Company、Johnson and Johnson等。

Merck &Co Inc.

概述

是一家专业从事处方药、生物治疗药物、疫苗和兽药的研究、开发、生产和营销的生物製药公司。我们提供心血管、癌症、免疫疾病、传染病、呼吸系统和妇女疾病的处方药，以及糖尿病药物。它销售动物保健产品，如疫苗、家禽、牛和水产养殖产品。Merck &Co Inc.为药品批发商、零售商、医院、政府机构和託管医疗机构提供药品，并向兽医、分销商和畜牧业者提供兽药。该公司的子公司和附属公司在美洲、欧洲、中东和非洲、亚太地区和拉丁美洲开展业务。

产品介绍

KEYTRUDA（派姆单抗）。KEYTRUDA 是一种处方药，用于治疗一种称为黑色素瘤的皮肤癌。用于患有 IIB 期、IIC 期和 III 期黑色素瘤的成人和 12 岁以上儿童，以帮助预防手术切除黑色素瘤和含有癌症的淋巴结后復发。

该报告提供了大约 45 多个市场数据表、40 多个图表和 180 页有关全球肿瘤学市场的信息。

目录

第一章 调查方法和范围

• 调查方法
• 市场范围

第二章主要趋势和发展

• 主要趋势和发展

第三章执行摘要

• 按治疗划分的市场细分
• 按类型划分的市场细分 DataM CLO 情景

第四章市场动态

• 市场影响因素
  • 促进者
    • 发病率增加
    • 司机 2
  • 抑製剂
    • 副作用的发生
    • 约束因素 2

第五章行业分析

• 波特五力分析
• 供应链分析
• 定价分析
• 监管分析
• 专利分析

第六章 按治疗方法

• 靶向治疗
• 免疫疗法
• 化学处理
• 放射治疗
• 其他

第 7 章 按类型

• 乳腺癌
• 肺癌
• 血癌
• 肾癌
• 血癌
• 前列腺癌
• 胃肠癌
• 妇科癌症
• 其他

第 8 章最终用户

• 医院
• 专科诊所
• 癌症和放射治疗中心

第9章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
• 中东/非洲

第 10 章按类型分列的市场规模及同比增长率分析 (%)

第 11 章 竞争格局

• 竞争情景
• 竞争对手战略分析
• 比较投资组合分析
• 市场/份额分析
• 併购分析

第十二章公司简介

• Pfizer, Inc.
  • 公司简介
  • 按类型和描述的投资组合
  • 主要亮点
  • 财务概览
• Novartis
• Amgen Inc
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Johnson and Johnson
• 其他

第 13 章 重要注意事项

第 14 章 重要注意事项 DataM

Market Overview

Oncology Therapy Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.3% during the forecast period (2022-2029).

Cancer therapies are medications designed to limit cancer growth and proliferation by interfering with specific molecules involved in the growth and expansion of malignant cells, such as proteins or DNA. Cancers of the lung, colorectal, breast, kidney and other organs are common in the population. The stage of disease progression primarily determines cancer treatment. It typically comprises radiotherapy, chemotherapy, surgery, and other cancer therapies. Immunotherapy, targeted therapy, hormone therapy, and stem cell transplant are now being researched and tested in clinical studies.

Market Dynamics

The major driving forces are the rise in cancer incidences, which has led to increased demand for cancer drugs, increased demand for precision medicine, increased number of collaborations between the pharmaceutical companies, increased recent advances in technology, and increased research activities in cancer, increasing geriatric population globally. In addition, the rise in healthcare expenditure worldwide and the rise.

An increase in the number of recent advances in technology and the use of information is expected to drive market growth.

Advanced medical devices, big data, artificial intelligence, and mobile apps drive better patient engagement. Big data has made treatments easier as it provides patient navigation, patient-reported outcomes, identification of high-risk patients, patient satisfaction scoring, and appropriate treatment. AI uses DL algorithms and convolutional neural networks (CNN), which analyze pixel-level information from images in oncology. For instance, the increasing usage of mobile apps in many nations results from technological advancements that can enhance cancer diagnosis, treatment, adherence, and other elements of the patient experience. In addition, Genentech approved a new medicine called Chimeric Antigen Receptor T-cell (CAR-T) therapy to improve CAR-T therapy. The therapy is quite expensive for patients, but an innovative pay-for-performance contract was also revealed in conjunction with the launch of the first CAR-T therapy to make it more accessible.

Furthermore, the new radio-labeled drug sustainability has lowered cancer patients' risk and death rate. The medicine is composed of radioisotope LU attached to octreotide that binds the tumor cells, enables the radiation, and directly targets the cancer cells. Thus, the recent advancements in technology are expected to boost the market.

Restraint:

However, the onset of adverse effects associated with the use of cancer drugs and high costs related to cancer drug development is among a few major factors expected to hamper the growth of the oncology therapy market.

Industry Analysis

The oncology therapy market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Targeted therapy segment is expected to hold the largest market share in the oncology therapy market.

The targeted therapy segment accounted for the largest market share in 2021. The segment benefited due to its fewer side effects offered by the treatment than the conventional therapy and cost-effective nature, and its increased number of dynamics. Moreover, the targeted therapy includes hormone therapies, apoptosis inducers, gene expression modulators, angiogenesis inhibitors, PARP inhibitors, signal transduction inhibitors, and toxin delivery molecules. These drugs inhibit the growth and spread of cancer cells and limit harm to normal cells. In addition, there are increasing FDA approvals in the region. For instance, Trodelvy (sacituzumab govitecan-hziy) was approved by the US Food and Drug Administration in April 2020 for treating adult patients with triple-negative breast cancer. Trodelvy is a drug combination of a Trop-2-directed antibody and a topoisomerase inhibitor that targets the Trop-2 receptor, which aids cancer growth, division, and dissemination. Furthermore, Tabrecta (capmatinib) was authorized by the US FDA in May 2020 to treat adult patients with non-small cell lung cancer (NSCLC), making it the first FDA-approved targeted medication to treat NSCLC with particular mutations. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global oncology therapy market.

North America accounted for the highest revenue share in 2021. The increasing prevalence of cancer, innovations in the cancer therapies, rising clinical trials for the therapies, increasing FDA approvals in the region and product launches by the market players are the factors to drive the market in the forecast period. For instance, For instance, according to the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States will be diagnosed. In contrast, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. Therefore, it has increased the adoption of oncology therapies. Moreover, the FDA approved Amgen's LUMAKRAS (sotorasib) in May 2021 to treat adult patients with KRAS G12C-mutated locally progressed or metastatic non-small cell lung cancer (NSCLC). Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the oncology therapy market are Pfizer, Inc., Novartis, Amgen Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson Others.

Merck & Co Inc.:

Overview:

Merck & Co Inc (Merck) is a biopharmaceutical firm specializing in researching, developing, producing, and marketing prescription medications, biologic therapies, vaccines, and animal health products. It provides prescription medications for cardiovascular, cancer, immunological disorders, infectious, respiratory, and women's diseases, as well as diabetic therapy. The company sells animal health items such as vaccinations, poultry, cattle, and aquaculture products. Merck offers pharmaceuticals to drug wholesalers, retailers, hospitals, government agencies, managed health care providers, and animal health products to veterinarians, distributors, and livestock producers. The company's subsidiaries and affiliates operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

Product Portfolio:

KEYTRUDA (pembrolizumab): KEYTRUDA is a prescription medicine used to treat: a kind of skin cancer called melanoma. It may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

The global oncology therapy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the market

2. Key Trends and Developments

• 2.1. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet By Treatment
• 3.2. Market Snippet By types DataM CLO Scenario

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising incidence
    • 4.1.1.2. Driver 2
  • 4.1.2. Restraints
    • 4.1.2.1. Onset of adverse effects
    • 4.1.2.2. Restraint 2

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Supply chain analysis
• 5.3. Pricing analysis
• 5.4. Regulatory analysis
• 5.5. Patent analysis

6. By Treatment

• 6.1. Introduction
• 6.2. Market size analysis, and y-o-y growth analysis (%), By Treatment segment
• 6.3. Market attractiveness index, By Treatment segment
• 6.4. Targeted therapy
  • 6.4.1. Introduction
  • 6.4.2. Market size analysis, y-o-y growth analysis (%)
• 6.5. Immunotherapy
  • 6.5.1. Introduction
• 6.6. Chemotherapy
• 6.7. Radiation therapy
• 6.8. Others

7. By Type

• 7.1. Introduction
• 7.2. Market size analysis, and y-o-y growth analysis (%), By Type segment
• 7.3. Market attractiveness index, By Type segment
• 7.4. Breast cancer
  • 7.4.1. Introduction
  • 7.4.2. Market size analysis, y-o-y growth analysis (%)
• 7.5. Lung cancer
  • 7.5.1. Introduction
• 7.6. Blood cancer
• 7.7. Kidney cancer
• 7.8. Hematological cancer
• 7.9. Prostate cancer
• 7.10. Gastrointestinal cancer
• 7.11. Gynecologic cancer
• 7.12. Others

8. By End-users

• 8.1. Introduction
• 8.2. Market size analysis, and y-o-y growth analysis (%), By End-users segment
• 8.3. Market attractiveness index, By End-users segment
• 8.4. Hospitals
  • 8.4.1. Introduction
  • 8.4.2. Market size analysis, y-o-y growth analysis (%)
• 8.5. Specialty clinics
  • 8.5.1. Introduction
• 8.6. Cancer and radiation therapy centers

9. By Region

• 9.1. Introduction
• 9.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
• 9.3. Market Attractiveness Index, By Region
• 9.4. North America
  • 9.4.1. Introduction
  • 9.4.2. Key region-specific dynamics
  • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
  • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
  • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
  • 9.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    • 9.4.6.1. U.S.
    • 9.4.6.2. Canada
    • 9.4.6.3. Mexico
• 9.5. Europe
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
  • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
  • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
  • 9.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    • 9.5.6.1. Germany
    • 9.5.6.2. U.K.
    • 9.5.6.3. France
    • 9.5.6.4. Italy
    • 9.5.6.5. Spain
    • 9.5.6.6. Rest of Europe
• 9.6. South America
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
  • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
  • 9.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
  • 9.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    • 9.6.6.1. Brazil
    • 9.6.6.2. Argentina
    • 9.6.6.3. Rest of South America
• 9.7. Asia Pacific
  • 9.7.1. Introduction
  • 9.7.2. Key Region-Specific Dynamics
  • 9.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment
  • 9.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type
  • 9.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By end-users
  • 9.7.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries
    • 9.7.6.1. China
    • 9.7.6.2. India
    • 9.7.6.3. Japan
    • 9.7.6.4. Australia
    • 9.7.6.5. Rest of Asia Pacific
• 9.8. The Middle East And Africa
  • 9.8.1. Introduction
  • 9.8.2. Key Region-Specific Dynamics
  • 9.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Treatment

10. Market Size Analysis, And Y-O-Y Growth Analysis (%), By type

11. Competitive Landscape

• 11.1. Competitive scenario
• 11.2. Competitor strategy analysis
• 11.3. Comparative type portfolio analysis
• 11.4. Market positioning/share analysis
• 11.5. Mergers and acquisitions analysis

12. Company Profiles

• 12.1. Pfizer, Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Type Portfolio And Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Novartis
• 12.3. Amgen Inc
• 12.4. AstraZeneca PLC
• 12.5. Bayer AG
• 12.6. Bristol-Myers Squibb Company
• 12.7. Johnson and Johnson
• 12.8. Others

13. Premium Insights

14. DataM Intelligence

• 14.1. Appendix
• 14.2. About us and services
• 14.3. Contact us